메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Muneaki Shimada (Tohoku University School of Medicine Sendai Japan) Kosuke Yoshihara (Niigata University Graduate School of Medical) Terumi Tanigawa (Department of Gynecologic Oncology Cancer Institute Hospital Tokyo Japan) Hiroyuki Nomura (Department of Obstetrics and Gynecology School of Medicine Fujita Health University Toyoake Japan) Junzo Hamanishi (Kyoto University) Satoe Fujiwara (Osaka Medical and Pharmaceutical University Takatsuki Japan) Hiroshi Tanabe (National Cancer Center Hospital East Kashiwa Japan) Hiroaki Kajiyama (Nagoya University) Masaki Mandai (Kyoto University Graduate School of Medicine) Daisuke Aoki (Keio University School of Medicine) Takayuki Enomoto (Niigata University School of Medicine Niigata Japan) Aikou Okamoto (The Jikei University School of Medicine)
저널정보
대한부인종양학회 Journal of Gynecologic Oncology Journal of Gynecologic Oncology Vol.34 No.3
발행연도
2023.5
수록면
1 - 7 (7page)
DOI
10.3802/jgo.2023.34.e62

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
The development of new treatments for gynecological malignancies has been conducted mainlythrough collaborative international phase III trials led by the United States and Europe. Thesur vival outcomes of many gynecological malignancies have greatly improved as a result. Recentlarge-scale genome-wide association studies have revealed that drug efficacy and adverse eventprofiles are not always uniform. Thus, it is important to validate new treatment options in eachcountr y to safely and efficiently provide newly developed treatment options to patients withgynecological malignancies. The Japanese Gynecologic Oncology Group (JGOG) is conducting5 cohort studies (JGOG 3026, 3027, 3028, 3030, and 3031) to establish real-world data (RWD)of poly(ADP-ribose) polymerase (PARP) inhibitor use in patients with advanced or recurrentepithelial ovarian cancer. The RWD constructed will be used to provide newly developedPARP inhibitors for women with advanced or recurrent ovarian cancer in a safer and moreefficient manner as well as to develop further treatment options. In 2022, The JGOG, KoreanGynecologic Oncology Group, Chinese Gynecologic Cancer Society, and Taiwanese GynecologicOncology Group established the East Asian Gynecologic Oncology Trial Group to collaboratewith East Asian countries in clinical research on gynecologic malignancies and disseminatenew knowledge on gynecologic malignancies from Asia. The JGOG will conduct a collaborativeintegrated analysis of the RWD generated from Asian countries and disseminate real-worldclinical knowledge regarding new treatment options that have been clinically implemented.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0